A sampling of Neurop's ongoing press releases.Copyright 2011 Neurop Inc.RSSviaXmlTextWriter v1.0http://neuropinc.com/news-detail.aspx?id=15NeurOp, Inc. was recognized by Georgia Bio with a Deal of the Year Award for its $3 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health to support its research program for ischemia. Announced in July 2011, N ...Thu, 26 Jan 2012 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=14ATLANTA, December 14, 2011 - NeurOp, Inc. today announced that Bristol-Myers Squibb (NYSE: BMY) has agreed to fund an additional year of research for NeurOp's proprietary small molecules for the treatment of major depression and neuropathic pain. " ...Wed, 14 Dec 2011 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=13ATLANTA, October 18, 2011 – NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that it is one of 40 companies selected to participate in the 2011-2012 Commercialization Assistance ...Tue, 18 Oct 2011 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=12ATLANTA, July 26, 2011 – NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that the National Institutes of Health (NIH) has awarded the company a $3 million grant to support it ...Tue, 26 Jul 2011 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=11ATLANTA, June 22, 2011 - NeurOp Corporation today announced that Robert R. Bonczek has been elected to the company's board of directors. He is president, CFO and general counsel at b3bio, Inc., a biotechnology company, and founding partner and presid ...Wed, 22 Jun 2011 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=10NeurOp, Inc. was the recipient of the Deal of the Year Award from Georgia Bio (GaBio) for its strategic partnership with Bristol-Myers Squibb, which was announced in March 2010. The annual awards ceremony recognizes transactions by life sciences ...Thu, 20 Jan 2011 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=9ATLANTA, November 16, 2010 - NeurOp Corporation today announced that Harold Shlevin, Ph.D., has joined its board of directors. Shlevin is a bioscience-industry executive with more than 30 years’ experience in medical devices, pharmaceuticals, diagn ...Tue, 16 Nov 2010 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=8NeurOp Corporation co-founder and Board of Directors’ member, Raymond J. Dingledine, Ph.D., was elected to the Institute of Medicine (IOM) at its 40th annual meeting in Washington, DC. Dr. Dingledine is executive associate dean for research and profe ...Sun, 10 Oct 2010 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=2ATLANTA, March 30, 2010 - NeurOp Corporation today announced a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused upon the development of NeurOp’s proprietary small molecules for use in the treatment of major depression and other c ...Tue, 30 Mar 2010 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=5ATLANTA, March 25, 2010 – NeurOp Corporation was named Start-Up Company of the Year at the Annual Celebration of Technology and Innovation sponsored by the Office of Technology Transfer at Emory University. Emory University's technology transf ...Thu, 25 Mar 2010 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=1ATLANTA, March 5, 2010 - NeurOp Corporation today announced that George (Barney) W. Koszalka has joined the company as President and Chief Executive Officer. As CEO, Dr. Koszalka will lead the company in a new growth phase to advance the company ...Fri, 05 Mar 2010 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=3ATLANTA, April 1, 2007 - NeurOp Corporation, a preclinical-stage pharmaceutical company focused on next generation drugs for central nervous system indications, announced today that it has closed on $500,000 in seed funding. "This is a significa ...Sun, 01 Apr 2007 04:00:00 GMThttp://neuropinc.com/news-detail.aspx?id=4ATLANTA, February 4, 2007 - NeurOp Corporation, a preclinical-stage pharmaceutical company focused on next generation drugs for central nervous system indications, announced today that it has received a Phase 1 SBIR award from the National Institut ...Sun, 04 Feb 2007 04:00:00 GMT